Target antigens defined by autoantibodies in IDDM include insulin, a putative glycolipid that reacts with islet cell antibodies, and a 64,000-/tf r protein recently identified as glutamic acid decarboxylase. In addition, some IDDM sera that contain antibodies to glutamic acid decarboxylase also coprecipitate a 38,000-M r protein from islets. This study used a high titer anti-38,000-M r serum to screen bacteriophage A. cDNA expression libraries and identified human islet and placental clones encoding jun-B, the nuclear transcription protein, of predicted 38,000 M r . Peripheral blood T-cells exhibited significant proliferation in response to a recombinant fragment of jun-B (amino acids 1-180) in 12 of 17 (71%) recent-onset IDDM subjects, 8 of 16 (50%) ICA-positive first-degree relatives of IDDM subjects who were at risk, 3 of 12 (25%) other autoimmune disease subjects, and 0 of 10 healthy control subjects. Proliferation to tetanus toxoid did not differ significantly between the groups. Responses to jun-B were not related to age, sex, or human leukocyte antigen status. Thus, autoreactive T-cells identify a novel antigen, p38 jun-B, in IDDM and appear to indicate subjects at risk for the development of clinical disease. Diabetes 42:626-30,1993
I
DDM is the outcome of an autoimmune process that destroys the pancreatic islet p-cells. Evidence includes a mononuclear cell infiltrate of the islets (insulitis) and circulating autoantibodies and T-cells that react to islet antigens (1) . Islet antigens that react with autoantibodies (2) include a putative glycolipid (3) , which is the target of ICA in frozen sections of human pancreas; insulin (4); and a 64,000-M r protein GAD (5-7). Recently, T-cells in the peripheral blood of recent-onset IDDM subjects and at-risk ICA-positive first-degree relatives of IDDM subjects have been shown to proliferate'to islets (8, 9 ) and specifically to insulin (8, 9) and GAD (10, 11) . In addition, Roep et al. (12, 13 ) generated T-cell lines from peripheral blood of recent-onset IDDM subjects to an uncharacterized 38,000-M r fraction of insulin secretory granule membranes.
Several other lines of evidence exist for a 38,000-/W r islet antigen. In the first study of the 64,000-/W r antigen (5) , some IDDM sera also precipitated a 38,000-/W r protein, which was overlooked. We have found that at least 33% of IDDM sera that immunoprecipitate the 64,000-/W r antigen from [ 35 S]methionine-labeled fetal porcine proislets also precipitate a 38,000-/W r protein (14) . In the autoimmune BB rat, a model of IDDM, antibodies to a 38,000-M r islet protein are reported to precede the onset of diabetes (15) . Finally, a mouse monoclonal antibody raised against human CMV by Pak et al. (16) reacted by immunoblotting with a 38,000-M r human islet-specific protein; Pak et al. (16) referred to unpublished data and claimed that antibodies to a 38,000-M r islet protein were present in IDDM subjects carrying CMV genome.
By screening human islet and placental cDNA X-phage expression libraries with an anti-64,000/ 38,000-M r IDDM serum, this study identified clones whose sequences were identical with the gene encoding the early response nuclear protein, jun-B (17), of pre-M.C. HONEYMAN AND ASSOCIATES dieted 38,000 M T . Because p-cell destruction in IDDM is mediated by T-cells (1), we investigated whether T-cells reactive with recombinant human jun-B are present in the peripheral blood of IDDM subjects and at-risk firstdegree relatives.
RESEARCH DESIGN AND METHODS
Sixteen at-risk first-degree relatives of IDDM subjects with ICA >20 JDF U (18), 17 with recent-onset IDDM within 6 wk of clinical diagnosis, 8 with Graves 1 disease, 4 with scleroderma, and 10 healthy, HLA-matched control subjects were studied with their informed consent and approval of the Royal Melbourne Hospital Human Ethics Committee. Identification and expression of jun-B cDNA clones. Serum from a recent-onset IDDM patient containing high titer antibodies that precipitated 64,000-M r GAD and a 38,000-M r protein from islets was used to immunoscreen human islet and placental cDNA expression libraries (islet library a gift from Dr. Alan Permutt, Washington School of Medicine, St. Louis, MO), as described by Young and Davis (19) . A total of 27 positive clones identified from the islet library and 18 from the placental library were plaque purified by repeated screening. Phage DNA was purified on CsCI step gradients, and insert sizes were determined by EcoRI restriction analysis. Sequencing of the 1.35-kb insert in the strongest immunoreactive clone from the islet library and comparison of its sequence against the Genbank protein data base revealed that the cDNA encoded the COOH-terminal 299 amino acids of the 347 amino acid jun-B. Sequencing of the 1.57-kb insert in the strongest immunoreactive clone from the placental library revealed that it encoded the full-length jun-B protein. Nucleotide sequencing was performed by the dideoxy chain termination method using the M13 vector primers and specific primers from the published DNA sequence of jun-B (17) . Full-length jun-B could not be expressed from either pGEX or hexahistidine fusion vectors in Escherichia coli. Truncated jun-B DNA encoding amino acids 1-180 was therefore generated by PCR using 5' and 3' primers containing SamHI and H/ndlll restriction sites, respectively, and cloned into the hexahistidine vector pDS56. After transformation of E. coli and inducement with 1 mM IPTG, the his 6 -jun-B fusion protein was affinity purified from 6 M guanidine HCI lysates on a nickel tetraacetate column (20) . The recombinant fusion protein was further purified by elution from a Bio-Rad (Richmond, CA) 491 preparative electrophoresis column and shown to resolve as a single band by SDS-PAGE (Fig. 1) .
As a control recombinant protein, GST from the pGEX vector, was expressed in E. coli and affinity purified on glutathione-agarose beads (11) . Protein was eluted from the beads with 10 mM reduced glutathione and 50 mM Tris-HCI, pH 8.0, dialyzed against human tonicity PBS, filter sterilized, and stored at -70°C. The eluted protein, apparent 26,000 M f , was homogeneous by SDS-PAGE. T-cell proliferation studies. PBMC were prepared from heparinized venous blood by Ficoll-Hypaque density centrifugation, washed twice, and resuspended at . jun-B (final concentrations 10, 1.0, and 0.1 |xg/ml) or thiomersal-free tetanus toxoid (CSL, Melbourne, Australia; final concentrations 1.78, 0.18, and 0.018 Lyons flocculating units/ml) were added in 10-ml vol to quadruplicate wells, and the trays were incubated at 37°C in 5% CO 2 -humidified air for 7 days. Cells were harvested semiautomatically 7 h after adding 1 ixCi/well of [ 3 H]thymidine (Amersham, Sydney, Australia, TRK61) and counted for (3-radioactivity. An SI was calculated as the ratio of the median counts per minute for the antigen concentration giving the highest stimulation to the median counts per minute in the absence of antigen. An increased SI was defined as Cl >95% (2.1) of the Sis of the healthy control subjects. The Sis of the control subjects were first log transformed because the distribution of Sis appeared to be skewed. Statistical significance between groups was determined by Wilcoxon's rank sum test.
RESULTS
Proliferation of peripheral blood T-cells in the presence of jun-B was greater than basal proliferation or proliferation in the presence of the control recombinant protein GST in most subjects tested ( Table 1) . Expression of the results as Sis highlighted the differences between each group (Fig. 2 ). Significant Sis (>2.1) to jun-B were found in 8 of 16 (50%) ICA-positive first-degree relatives, 12 of 17 (71%) recent-onset IDDM subjects, 2 of 8 (25%) Graves' disease subjects, 1 of 4 (25%) scleroderma subjects, and 0 of 10 healthy control subjects. The number of recent-onset IDDM subjects responding to jun-B was 
FIG. 2. Proliferation (SI) of peripheral blood T-cells in response to jun-B.
significantly higher than ICA-positive first-degree relatives (P < 0.05), subjects with Graves' disease or scleroderma (P< 0.005), and healthy control subjects (P< 0.0005). The responses to tetanus toxoid did not differ significantly between the groups. No significant differences were observed between responders and nonresponders with respect to age, sex, HLA status, or basal counts per minute.
DISCUSSION
jun-B is a nuclear transcription factor that dimerizes through its leucine zipper with related proteins, e.g., c-fos (21) . T-cell responses to jun-B in the majority of subjects with recent-onset IDDM, 50% of the at-risk first-degree relatives of IDDM subjects, and a minority of subjects with other autoimmune disease were specific, in that the groups were not distinguished by different levels of T-cell responses to tetanus toxoid. Furthermore, the apparent lack of association between T-cell responses and specific class II HLA alleles indicates that the differences were not just the result of the presentation of jun-B peptides by IDDM susceptibility alleles (e.g., DR3.4 or DQ2.8) but to an increase in the number or responsiveness or both of T-cells that recognize jun-B peptides. To our knowledge, this is the second example of a nuclear protein autoantigen defined by T-cells in humans, the other being the p70 protein of U1 ribonucleoprotein in mixed connective tissue disease (22) . Two subjects with Graves' disease and one with active scleroderma also had increased responses, as defined. This overlap may not be unexpected as the cutoff for an increased response is arbitrary, and specificity and sensitivity need to be defined from the analysis of much larger disease and control groups. Biologically, it is consistent with the idea that autoreactivity is a continuous variable. Furthermore, a known association, both clinically and serologically, exists between IDDM and other autoimmune diseases, especially Graves' disease. Operationally, our findings indicate that T-cell reactivity to jun-B, or a molecule with crossreactive epitopes, is a risk marker for IDDM. Confirmation requires longitudinal studies of at-risk individuals followed to clinical disease. Not all at-risk ICA-positive first-degree relatives develop diabetes (18) . Interestingly, the frequency of T-cell responses to jun-B was higher in recent-onset IDDM subjects than in relatives, suggesting that the relatives with reactivity to jun-B are at higher risk.
We were unsuccessful in expressing the full-length jun-B protein and therefore were unable to investigate its reactivity with a panel of IDDM sera. The truncated recombinant protein (amino acids 1-180) used for the T-cell studies reacted by immunoblotting with <10% of IDDM sera (data not shown). Although retaining linear epitopes for autoreactive T-cells, the recombinant proteins may lack dominant antibody epitopes, and autoantibody binding to jun-B may be conformation dependent.
Nuclear proteins are targets of autoantibodies that characterize systemic autoimmune connective tissue diseases such as systemic lupus erythematosus (23) but may also be targeted by autoantibodies in restricted tissue-or organ-specific autoimmune diseases, e.g., the La ribonucleoprotein in Sjogren's syndrome. Although useful as disease markers, the relevance of autoantibodies to these ubiquitous proteins in the pathogenesis of disease remains unclear. Given that jun-B is not specific for p-cells, how can our findings be reconciled with the immunopathology of IDDM and with reports (12-16) of a 38,000-M r islet antigen in IDDM? jun-B is an early response nuclear protein in many cells (24, 25) and, although transiently expressed in response to growth factors, can be expressed in stable form under certain conditions, e.g., in myeloid cells terminally differentiating in response to IL-6 (26) or in sympathetic neurones switched from a noradrenergic to cholinergic phenotype in response to leukemia inhibitory factor (27) . By analogy, jun-B might be expressed in stable form in the terminally differentiated (S-cell or upregulated by inflammatory cytokines or both including the IL-6 present in the islet lesion (28, 29) . Specificity of an anti-jun-B T-cell response would require processing and presentation of islet (p-cell)-specific jun-B epitopes or the persistent effect of a p-cell cytotropic virus (30) or both, or chemotoxin (31) to induce aberrant expression of jun-B. Roep et al. (12, 13 ) generated T-cell lines from IDDM subjects to a 38,000-/W r fraction of insulin secretory granules. Although secretory granules would not be expected to contain jun-B, after isolation they appear to be contaminated by a multiplicity of proteins; moreover, the T-cell lines reacted not only with 38,000-M r granule fraction but also with the pellet fraction that contained endoplasmic reticulum (13) . Conceivably, these T-cell lines may have been generated to jun-B, and this possibility should be the subject of future experiments.
Pak et al. (16) described a monoclonal antibody to human CMV that immunoblotted a 38,000-H human (but not mouse or rat) islet protein. Molecular mimicry, the sharing of an epitope between a CMV protein and a 38,000-H islet protein, could result in anti-CMV immunity being directed against the islet. Data-base analysis (FASTA and T FASTA search programs) reveals that jun-B shares amino acid sequences with human CMV (AD169 strain) and related herpes viruses. For example, GRAPGGL at positions 21-27 near the NH 2 -terminus of jun-B is present in human CMV amino acid 44963-44968, Epstein-Barr virus amino acid 11231-11236, and HSV (replication-associated long unique region) amino acid 32640-32645. The sequence ELERLIV at positions 86-92 of jun-B is present in CMV amino acid 443-449 (glycoprotein-B, neutralization epitope related), and amino acid 1411-1417 (major capsid protein). The sequence REQVAQ at positions 318-323 near the COOHterminus of jun-B is present in CMV amino acid 50232-50237 and in HSV1-transforming domain shares five of six amino acids in positions 136-141. The first two of these sequences occur in the jun-B fusion protein used here to elicit T-cell reactivity in IDDM subjects. If further studies were to demonstrate that T-cells recognize one or other of these sequences, target cell specificity would require their presentation uniquely on p-cells or antigenpresenting cells in the islet. Although the pathogenic role of T-cell reactivity to jun-B requires further investigation, these findings indicate that jun-B-reactive T-cells are a marker of subjects at risk for clinical disease. These findings raise the possibility that autoimmunity to oncogene products might be more prevalent than realized up to this time.
